Cybin completes enrollment in phase 2 study of cyb003 in major depressive disorder

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has completed enrollment in its phase 2 study of cyb003, a proprietary deuterated psilocybin analog program being developed for the potential treatment of major depressive disorder (“mdd”). all participants in t.
CYBN Ratings Summary
CYBN Quant Ranking